PB2636: VAYHIT1: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PHASE III TRIAL OF IANALUMAB VERSUS PLACEBO IN ADDITION TO FIRST-LINE CORTICOSTEROIDS IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)

• Nichola Cooper,
• Adam Cuker,
• Marc Michel,
• Raymond Wong,
• Waleed Ghanima,
• Francesco Zaja,
• Wilma Barcellini,
• Fengkui Zhang,
• Tomasz Lawniczek,
• Marine Weill,
• Hanny Al-Samkari

Affiliations

Nichola Cooper

1 Imperial College London, Department of Inflammation and Immunity, London, United Kingdom

Adam Cuker

2 Perelman School of Medicine, University of Pennsylvania, Department of Medicine and Department of Pathology and Laboratory Medicine, Philadelphia, PA, United States

Marc Michel

3 Henri Mondor University Hospital, Assistance Publique-Hôpitaux de Paris, Paris-Est Créteil University, Department of Internal Medicine, Créteil, France

Raymond Wong

4 The Chinese University of Hong Kong, Department of Medicine and Therapeutics, Shatin, Hong Kong

Waleed Ghanima

5 Østfold Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway

Francesco Zaja

6 DSM, University of Trieste and Department of Hematology, Azienda Sanitaria Universitaria Giuliano-Isontina, Trieste, Italy

Wilma Barcellini

7 Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy

Fengkui Zhang

8 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Anemia Therapeutic Center, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China

Tomasz Lawniczek

9 Novartis, Basel, Switzerland

Marine Weill

9 Novartis, Basel, Switzerland

Hanny Al-Samkari

10 Harvard Medical School, Massachusetts General Hospital, Division of Hematology Oncology, Boston, MA, United States